Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate

被引：0
|
作者：
Espinet, Blanca [1 ,3 ]
Carla Oliveira, Ana [2 ]
Boque, Concepcion [2 ]
Domingo, Alicia [2 ]
Alonso, Esther [2 ]
Sole, Francesc [1 ,3 ]
机构：
[1] Hosp del Mar, Lab Citogenet & Biol Mol, Serv Patol, IMAS,URNHE PRBB, Barcelona, Spain
[2] Hosp Univ Bellvitge, Serv Hematol, ICO, Barcelona, Spain
[3] Escola Citol Hematol Soledad Woessner IMAS, Barcelona, Spain
来源：
HAEMATOLOGICA | 2005年 / 90卷 / 04期
关键词：
chronic myeloid leukemia; clonal cytogenetic abnormalities; imatinib;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The emergence of clonal chromosomal abnormalities in Philadelphia-negative cells during treatment with imatinib in patients with Philadelphia-positive chronic myeloid leukemia has been reported. We add information to this issue presenting a series of 29 patients in complete cytogenetic response after imatinib treatment, three of whom developed clonal aberrations.
引用
收藏
页码：556 / 558
页数：4
相关论文
共 50 条
  • [21] Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α
    Branford, Susan
    Hughes, Timothy
    Milner, Alvin
    Koelmeyer, Rachel
    Schwarer, Anthony
    Arthur, Chris
    Filshie, Robin
    Moreton, Susan
    Lynch, Kevin
    Taylor, Kerry
    CANCER, 2007, 110 (04) : 801 - 808
  • [22] Changes of Immunological, Cytogenetic and Haematological Profiles in Chronic Myeloid Leukemia Treated with Imatinib Mesylate
    Gaiz, Almottesembellah
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S286 - S286
  • [23] Cytogenetic remissions induced by interferon α and imatinib mesylate are immunologically distinct in chronic myeloid leukemia
    Nakayama, Shin
    Nagamura-Inoue, Tokiko
    Yokoyama, Kazuaki
    Ohno, Nobuhiro
    Ooi, Jun
    Takahashi, Satoshi
    Uchimaru, Kaoru
    Iseki, Toru
    Tojo, Arinobu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 86 (03) : 208 - 211
  • [24] Cytogenetic remissions induced by interferon α and imatinib mesylate are immunologically distinct in chronic myeloid leukemia
    Nakayama S.
    Nagamura-Inoue T.
    Yokoyama K.
    Ohno N.
    Ooi J.
    Takahashi S.
    Uchimaru K.
    Iseki T.
    Tojo A.
    International Journal of Hematology, 2007, 86 (3) : 208 - 211
  • [25] CYTOGENETIC EVALUATION OF RESPONSE TO IMATINIB MESYLATE IN THE TREATMENT OF CHRONIC GRANULOCYTIC LEUKEMIA IN PEDIATRICS
    Olaya, Alberto
    Juarez, Francisco
    Perez-Garcia, Martin
    PEDIATRIC BLOOD & CANCER, 2010, 55 (05) : 866 - 866
  • [26] Clonal cytogenetic abnormalities have negative effects on survival of chronic myeloid leukemia (CML) patients treated with imatinib mesilate.
    Moreira, VA
    Desperati, P
    Setubal, DC
    Bonfim, CM
    Bitencourt, MA
    Lima, DH
    Netto, JZ
    Medeiros, CR
    Pasquini, R
    BLOOD, 2003, 102 (11) : 322B - 322B
  • [27] Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature
    Tsimberidou, AM
    Medina, J
    Cortes, J
    Rios, A
    Bonnie, G
    Faderl, S
    Kantarjian, H
    Garcia-Manero, G
    LEUKEMIA RESEARCH, 2004, 28 (06) : 657 - 660
  • [28] Complete cytogenetic response to cytarabine-containing chemotherapy and imatinib mesylate in a patient with acute blastic phase of chronic myeloid leukemia (CML).
    Kalla, H
    Lerma, P
    Besa, EC
    BLOOD, 2003, 102 (11) : 250B - 251B
  • [29] Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year
    Russo, Domenico
    Baccarani, Michele
    Martinelli, Giovanni
    Colombi, Chiara
    Malagola, Michele
    Skert, Cristina
    Soverini, Simona
    Iacobucci, Ilaria
    Turri, Diamante
    Mirto, Salvatore
    Gobbi, Marco
    Pierri, Ivana
    Vitolo, Umberto
    Pregno, Patrizia
    Fogli, Miriam
    Testoni, Nicoletta
    De Vivo, Antonio
    Castagnetti, Fausto
    Morra, Enrica
    Pungolino, Ester
    Di Raimondo, Francesco
    Stagno, Fabio
    Alimena, Giuliana
    Breccia, Massimo
    Nobile, Francesco
    Martino, Bruno
    Rambaldi, Alessandro
    Intermesoli, Tamara
    Saglio, Giuseppe
    Cambrin, Giovanna Rege
    Visani, Giuseppe
    Nicolini, Giuseppina
    de Fabritiis, Paolo
    Abruzzese, Elisabetta
    Fanin, Renato
    Tiribelli, Mario
    Galieni, Piero
    Bigazzi, Catia
    Specchia, Giorgina
    Angelucci, Emanuele
    Usala, Emilio
    Musolino, Caterina
    Russo, Sabina
    Gaidano, Gianluca
    Lunghi, Monia
    Lauria, Francesco
    Bocchia, Monica
    Rodeghiero, Francesco
    D'Emilio, Anna
    Bosi, Alberto
    BLOOD, 2011, 118 (21) : 730 - 731
  • [30] Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia
    Rosti, G
    Trabacchi, E
    Bassi, S
    Bonifazi, F
    De Vivo, A
    Martinelli, G
    Alberti, D
    Fincato, G
    Saglio, G
    Baccarani, M
    HAEMATOLOGICA, 2003, 88 (03) : 256 - 259
12345